 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | MSN LABORATORIES PRIVATE LIMITED |
| Street 1: | H. No: 2-91/10&11/ MSN |
| Street 2: | WHITEFIELDS, KONDAPUR |
| City: | HYDERABAD |
| Province: | |
| Post Code: | 500084 |
| Country: | India |
| Phone: | 7893621136 |
| Organization Email: | santanu.de@msnlabs.com |
| Web Site: | http://www.msnlabs.com/ |
| Other Online Presence: | http://novadozpharma.com/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | U24239TG2003PTC041583 |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| MSN group is a leading Pharmaceutical manufacturer with the highest number of active US DMFs. We have several US FDA, EU, WHO approved API plants and also state of the art US FDA/EU/WHO approved formulation plants for manufacturing oral solids and parenteral products both in the Hyderabad, India as well as Piscataway, NJ, US. Our facilities are approved by many emerging market regulatory authorities also. We have strong marketing presence in India and Emerging markets. In our fight against COVID we have launched Favipiravir to 170 cities free of cost to COVID patients. We are also manufacturing Remdesivir (generic of Veklury) to a Gilead licensee. We also collaborated with Eli Lilly to bring Baricitinib in India to treat COVID and are also license holders on Molnupiravir and Paxlovid for more than 100 countries. One of the products that we alreday developed is Bedaquiline and through this opportunity would like to leverage our cost competetive and large manufacturing scale and supply this medicine to needy patients all over the world. We are interested in seeking license from you and accordingly act |
|
| Do you know about the UNHLM declaration: | No |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 0 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Resource mobilization |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Since 2018 MSN has developed the Bedaquiline API and is in the first to file API DMF in US. We have also developed the formulation and filed for WHO-PQ.We are expecting approval anytime now | |
Geographical Reach | |
| Which country is your headquarters located in: | India |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Afghanistan Albania Algeria Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bangladesh Barbados Belarus Belgium Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Central African Republic Chad Chile China Colombia Congo Costa Rica Cote d'Ivoire Croatia Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Estonia Ethiopia Finland France Gabon Gambia Georgia Germany Ghana Greece Guatemala Guinea Guinea-Bissau Honduras Hungary Iceland India Indonesia Iran (Islamic Republic of) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Lithuania Luxembourg Madagascar Malawi Malaysia Maldives Mali Malta Mauritius Mexico Mongolia Morocco Mozambique Myanmar Namibia Nepal Netherlands New Zealand Niger Nigeria Norway Oman Pakistan Panama Paraguay Peru Philippines Poland Portugal Qatar Republic of Moldova Romania Russian Federation Rwanda Saudi Arabia Senegal Seychelles Singapore Slovakia Slovenia South Africa Spain Sri Lanka Sudan Sweden Switzerland Thailand Togo Trinidad and Tobago Tunisia Turkey Uganda Ukraine United Arab Emirates United Kingdom of Great Britain and Northern Ireland United Republic of Tanzania United States of America Uruguay Uzbekistan Venezuela Viet Nam Yemen Zambia Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New TB Drugs: We have already developed Bedaquiline product and API. We have filed for WHO PQ for the formulation. In our pipeline we are working on Pretomanid and Delamanid. Our strength of R&D and large manufacturing scale can ensure robust quality and timely supply of the medicines at very cost competetive rates Research: MSN has one of the largest R&D centers in India and in US and have talented pool of scientists and all necessary advance tool for analysis. There are several TB related drugs in our pipeline in which we are currently working |
|
Declaration | |
| Declaration of interests: We believe we don`t have any conflict of interest on this regard. Through IDA and I believe going forward through i+ solutions MSN is providing Levofloxacin and Moxifloxacin TB drugs. | |
| Application date: | July 19, 2023 |
| Last updated: | July 19, 2023 |